TY - JOUR
T1 - Exploiting CRISPR-Cas immune systems for genome editing in bacteria
AU - Barrangou, Rodolphe
AU - van Pijkeren, Jan Peter
N1 - Funding Information:
RB and JPvP are supported by start-up funds from North Carolina State University and the University of Wisconsin–Madison , respectively. JPvP acknowledges the Food Research Institute at UW-Madison for their financial support. The authors would like to thank their many colleagues and collaborators in the CRISPR field for their insights into these fantastic molecular systems.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The CRISPR-Cas immune system is a DNA-encoded, RNA-mediated, DNA-targeting defense mechanism, which provides sequence-specific targeting of DNA. This molecular machinery can be engineered into the sgRNA:Cas9 technology, for programmable cleavage of DNA. Following the genesis of double-stranded DNA breaks, the DNA repair machinery generates mutations at the cleavage site using various pathways. This technology has revolutionized eukaryotic genome editing, and we are at the cusp of full exploitation in bacteria. Here, we discuss the potential of CRISPR-based technologies for use in bacteria, and highlight the application of single stranded DNA recombineering combined with CRISPR-Cas selection to edit the genome of a probiotic organism. We envision that CRISPR-Cas technologies will play a key role in the development of next-generation industrial bacteria.
AB - The CRISPR-Cas immune system is a DNA-encoded, RNA-mediated, DNA-targeting defense mechanism, which provides sequence-specific targeting of DNA. This molecular machinery can be engineered into the sgRNA:Cas9 technology, for programmable cleavage of DNA. Following the genesis of double-stranded DNA breaks, the DNA repair machinery generates mutations at the cleavage site using various pathways. This technology has revolutionized eukaryotic genome editing, and we are at the cusp of full exploitation in bacteria. Here, we discuss the potential of CRISPR-based technologies for use in bacteria, and highlight the application of single stranded DNA recombineering combined with CRISPR-Cas selection to edit the genome of a probiotic organism. We envision that CRISPR-Cas technologies will play a key role in the development of next-generation industrial bacteria.
UR - http://www.scopus.com/inward/record.url?scp=84947930171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947930171&partnerID=8YFLogxK
U2 - 10.1016/j.copbio.2015.10.003
DO - 10.1016/j.copbio.2015.10.003
M3 - Review article
C2 - 26629846
AN - SCOPUS:84947930171
SN - 0958-1669
VL - 37
SP - 61
EP - 68
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
ER -